Nasdaq

Pfizer and BioNTech’s COMIRNATY® Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19

The 2025-2026 COVID-19 vaccine formulation targets the SARS-CoV-2 sublineage LP.8.1, in line with FDA guidance to more closely match circulating strains1 Shipping of the LP.8.1-adapted vaccine will ...
U.S. News & World Report

Pfizer Slashes Stake in COVID Vaccine Partner BioNTech

(Reuters) -Pfizer Inc said on Thursday it sold a part of its stake in German drugmaker BioNTech SE, more than five years after both firms formed an alliance that yielded a vaccine to combat the ...
Becker's Hospital Review

Pfizer to sell $508M stake in BioNTech

Pfizer is selling its remaining stake in COVID-19 vaccine partner BioNTech. The U.S. drugmaker is offering about 4.55 million American depositary receipts in an overnight block trade, marketed at ...

BioNTech outlines €2B–€2.3B revenue target for 2026 while advancing late-stage oncology pipeline and leadership transition

Q4 2025 Management View CEO Ugur Sahin highlighted that BioNTech maintained its leadership in the COVID vaccine market, launching a variant-adapted vaccine in partnership with Pfizer, now distributed ...
Benzinga.com

4PFE, BNTX : Pfizer, Moderna, BioNTech Stocks Tumble...

Shares of COVID-19 vaccine makers Pfizer Inc (NYSE:PFE), BioNTech SE ADR (NASDAQ:BNTX) and Moderna Inc (NASDAQ:MRNA) are trading lower Friday following a Washington Post report that Trump ...